OS Therapies to report significant survival benefit for OST-HER2 in osteosarcoma

OS Therapies is expected to report today that its lead immunotherapy candidate, OST-HER2, has achieved a statistically significant overall survival benefit at 2.5 years in patients with fully resected ...

OS Therapies says new bone cancer data strengthens case for regulatory filings

OS Therapies Incorporated OSTX shares are up during Tuesday’s premarket session as the company recently announced that its ...
Business Wire

OS Therapies Presents Statistically Significantly Positive 1-Year Event Free Survival, Overall Survival and Safety Clinical Data Updates for OST-HER2 at the MIB Agents Factor ...

The primary endpoint of 12-month Event Free Survival (EFS) for OST-HER2- treated patients (35%) was statistically significant (p= 0.0194) when compared with peer-reviewed comparable historical control ...
Nasdaq

OS Therapies Announces Statistically Significant Positive Interim 2-Year Overall Survival Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent ...

New York, New York--(Newsfile Corp. - August 7, 2025) - OS Therapies (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) ...
Nature

Osteosarcoma Treatment and Prognosis

Osteosarcoma is the most common primary malignant bone tumour, predominantly affecting adolescents and young adults. Standard management combines wide surgical resection with multiagent chemotherapy, ...
ascopubs.org

Postrelapse Survival in Osteosarcoma of the Extremities: Prognostic Factors for Long-Term Survival

Purpose: To identify factors that influence postrelapse survival (PRS) in patients with nonmetastatic osteosarcoma of the extremity Patients and Methods: One hundred sixty-two patients with recurrent ...